Treatment of Ovarian Cancer with Malignant Pleural and Ascites Fluid Using Recombinant Modified Human Tumor Necrosis Factor Combined with Hyperthermic Intraperitoneal Chemotherapy: A Case Report
Abstract：Ovarian cancer is one of the most common malignant tumors of the female reproductive system, with an incidence rate second only to cervical cancer and endometrial cancer. In recent years, the incidence of ovarian cancer has shown a year-by-year increasing trend, and its mortality rate ranks first among malignant tumors of the female reproductive system, seriously threatening women's health [1-2]. Due to the non-specific early symptoms, about 70% of patients are diagnosed at an advanced stage, often accompanied by widespread pelvic and abdominal cavity metastasis and the formation of malignant pleural and ascitic fluid, with a poor prognosis. Since 1986, intraperitoneal hyperthermic chemotherapy has been applied in the treatment of ovarian cancer. In 1999, the first successful case of combining hyperthermia with surgery for the treatment of ovarian cancer was reported.
Keywords：Recombinant modified human tumor necrosis factorOvarian cancerPleural and ascitic fluidHyperthermic intraperitoneal chemotherapy
Publication Date：2025-06-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 623-624 )